Navigation Links
Dr. Dennis Fenton and Dr. Steve Kaldor Join Amira Board of Directors
Date:3/31/2008

SAN DIEGO, March 31 /PRNewswire/ -- Amira Pharmaceuticals, a small molecule pharmaceutical company focused on the discovery and development of compounds to treat inflammatory disease, today announced the appointment of two additional members to its board of directors: Dennis M. Fenton, Ph.D. and Stephen W. Kaldor, Ph.D.

Dr. Fenton has 30 years of pharmaceutical and biotechnology experience, including over two decades at Amgen where he played an instrumental role in the development of the company into a global, fully-integrated, multi-billion dollar organization. Fenton's broad background includes executive leadership roles in manufacturing, process development, sales and marketing, operations and quality control. His most recent role at Amgen was as Executive Vice President of Operations.

Fenton holds a B.S. in Biology from Manhattan College and a Ph.D. in Microbiology from Rutgers University.

"Dennis is a biotechnology pioneer," said chief executive officer, Bob Baltera. "His experience and insight from his years at Amgen will be extremely useful for Amira as we plan our future. In addition to Dennis, we are also very pleased that Steve Kaldor will join our board of directors. Steve's experience in successful start-up companies further deepens our pool of experience and knowledge and I'm sure he will serve as a great partner for us."

Dr. Kaldor is currently president and chief executive officer of Ambrx, a private biotechnology company focused on the development of next-generation, protein-based medicines. Prior to joining Ambrx, Kaldor served as president and chief scientific officer of Syrrx, a structure-based drug discovery company, which he led through its $270 million acquisition by Takeda in 2005. He also spent over twelve years in various research and development roles at Eli Lilly and is a co-inventor of Viracept(R), a marketed AIDS drug.

Kaldor holds a B.S. in Chemistry from Columbia University and a Ph.D. in Organic Chemistry from Harvard University.

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of compounds to treat inflammatory disease.

The company combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient and effective pre-clinical and clinical program decisions. Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair(R). The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future.

In February 2008, Amira Pharmaceuticals and GlaxoSmithKline entered a global agreement for Amira's FLAP inhibitor program. The deal follows positive phase 1 data from novel product candidate AM103 for the oral treatment of respiratory disease.

Amira has raised $40 million to date from investors including Novo A/S (Copenhagen, Denmark), Avalon Ventures (San Diego, CA), Prospect Ventures (Palo Alto, CA) and Versant Ventures (Menlo Park, CA). For more information, visit http://www.amirapharm.com.


'/>"/>
SOURCE Amira Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Dennis Joyce Joins Executive and Board Search Firm Hodge / Niederer / Cariani / Lindsay
2. Bacchus Vascular Names Dennis Rosenberg as Vice President of Marketing
3. Kendle Executive Dennis Hurley, DrSc to Present Keynote Address at DIA Latin American Congress 2007
4. TIGroup Names Dennis M. Smith as Chief Financial Officer
5. Dr. Steve Liu, CEO of Ingenious Med, Joins Benchmarks Committee at SHM
6. Stevens chemists identify compounds to lure nutria, a rat-like pest ravaging Gulf Coast wetlands
7. Northwestern Memorial Hospitals Steven J. Stryker MD Unveils Campaign With Empower Public Relations
8. Stevens UV expert at Science-on-Saturday program
9. Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on New SAMHSA Study On Cough Medicine Abuse
10. Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on the Release of the 2007 Monitoring the Future Study
11. Play by Steve Nash, Assisted by Milk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2017)... ... ... Viewers likely know Rob Lowe from such 80s hits as St. Elmo’s Fire and ... The West Wing and Parks and Recreation. But recently, Lowe’s leant his talents to ... on important modern-day issues that face today’s society. One of the most recent episodes ...
(Date:5/27/2017)... ... May 27, 2017 , ... Hate visiting the dentist? You should go twice per ... take care of your teeth at home. Here are some dental tips to help out: ... a small toothbrush in your work desk or a locker at school for a quick ...
(Date:5/27/2017)... ... May 27, 2017 , ... From May 21-23, hearing healthcare ... three-day event was held at the Marriott Syracuse Downtown Hotel in Syracuse, New York. ... and network of independent hearing healthcare providers to help them stay ahead in the ...
(Date:5/26/2017)... ... ... Mediaplanet is proud to announce the launch of its newest edition of ... on how to take care of all aspects of their skin. , On the ... with the Stars professional, Witney Carson, shares her journey with the disease that nearly ...
(Date:5/26/2017)... ... 26, 2017 , ... Leading CEOs from biotech, pharmaceutical, and ... 31st at The Four Seasons Hotel Boston. , The Boston CEO Conference ... exclusive access to key decision makers who influence deal making and investment. Attendees ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... CSSi, the global leader in patient recruitment, ... is proud to announce the launch of its newly ... both enriched content and a customized layout that provides ... already well-established position as the top global patient recruitment ... months of hard work, we are delighted to officially ...
(Date:5/9/2017)... 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug ... Property Office has granted Oramed a patent titled, ... The patent covers Oramed,s invention of an oral ... an incretin hormone that stimulates the secretion of ...
(Date:5/8/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO)., has completed its acquisition ... care service center company based in Chantilly, ... management programs for leading pharmaceutical manufacturers and health care ... will join Envoy Health Management, LLC , as ... firms, and other service companies. Together, WRB and EnvoyHealth ...
Breaking Medicine Technology: